Melinda L. Telli, MD, on Choosing Among Many Treatment Options for HER2-Positive Breast Cancer

Posted: Wednesday, April 14, 2021

Melinda L. Telli, MD, of Stanford Cancer Institute, discusses how the updated NCCN Clinical Practice Guidelines in Oncology® can help physicians approach treatment decisions for individual patients with HER2-positive breast cancer, given the many options now available, including tucatinib, margetuximab, trastuzumab, and neratinib.